VIEW
SHAREOverview
Bronchopulmonary dysplasia (BPD) is an inflammatory lung disease affecting preterm infants and a source of major morbidity and significant mortality. Its etiology is multifactorial. BPD and its complications can rarely lead to death well beyond the neonatal period and in this small group of severely affected infants the management is challenging and controversial.
Most Recent References
Comparing Low-Dose (DART) and Enhanced Low-Dose Dexamethasone Regimens in Preterm Infants with Bronchopulmonary Dysplasia. Al-taweel HM, Abdelhady ISI, Irfan N, Khzzam FA, Kamal A, Thazhe SBK, Bayoumi MAA and, Gad A. Front Pediatr. 2023; 11: 1261316
The Canadian Neonatal Network: Annual Report 2022. Beltempo M, Shah P, Tyoon EW, Goswami N and, Members of the Annual Report Review Committee. 2022.
Late (≥ 7 days) Systemic Postnatal Corticosteroids for Prevention of Bronchopulmonary Dysplasia in Preterm Infants. Cochrane Neonatal Group, Doyle LW, Cheong Jl, Hay S, Manley BR and, Halliday HL. Cochrane Database Syst Rev. 2021; 2021(11): CD001145.